Longdaysin

Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively[1][2].

Product Specifications

CAS Number

[1353867-91-0]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Casein Kinase; CDK; ERK; Wnt

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/longdaysin.html

Purity

99.83

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

FC(F)(F)C1=CC=CC(CNC2=NC=NC3=C2N=CN3C(C)C)=C1

Molecular Formula

C16H16F3N5

Molecular Weight

335.33

Precautions

H315, H319

References & Citations

[1]Griffett K, et al. The mammalian clock and chronopharmacology. Bioorganic & Medicinal Chemistry Letters, 2013, 23 (7) :1929-1934..|[2]Hirota T, et al. High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol. 2010 Dec 14;8 (12) :e1000559.|[3]Xiong Y, et al. Longdaysin inhibits Wnt/β-catenin signaling and exhibits antitumor activity against breast cancer. Onco Targets Ther. 2019 Feb 5;12:993-1005.